20:15 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

DISEASE CATEGORY: Musculoskeletal INDICATION: Bone repair Cell culture and non-human primate studies identified chimera composed of BMP2, BMP6 and activin A sequences that could help repair bone.The chimera consists of human BMP2 engineered with substitutions...
18:24 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Genfit's elafibranor meets in Phase II for primary biliary cholangitis

Genfit S.A. (Euronext:GNFT) said both doses of elafibranor (GFT505) met the primary endpoint in a Phase II trial to treat primary biliary cholangitis (PBC). The company said it believes the strength of the data qualify...
17:30 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
23:05 , Nov 5, 2018 |  BC Extra  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
18:03 , Oct 25, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Bioinformatics screens A bioinformatics screen based on transcriptomic data sets could help identify new targets for approved drugs. The screen involved 3 steps: analyzing 2,052 genes from eight signaling pathways in data sets from...
16:39 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Viking's VK2809 meets in Phase II for NAFLD

Viking Therapeutics Inc. (NASDAQ:VKTX) reported that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD). The company plans to meet with FDA early next year...
21:04 , Sep 18, 2018 |  BC Extra  |  Clinical News

Viking gains on Phase II NAFLD data

Viking Therapeutics Inc. (NASDAQ:VKTX) added $9.07 (87%) to $19.46 on Tuesday after reporting that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease. The move translates...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM reports Phase II data for NGM282 in primary sclerosing cholangitis

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported additional data from a Phase II trial in 62 primary sclerosing cholangitis (PSC) patients with elevated alkaline phosphatase levels showing that once-daily subcutaneous 3 mg NGM282 significantly...
17:58 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Intercept's Ocaliva improves fibrosis in subgroup of primary biliary cholangitis patients

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) reported data from a subgroup of 13 primary biliary cholangitis (PBC) patients with liver fibrosis or cirrhosis at baseline and who had paired liver biopsies in the Phase III POISE trial...
13:39 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

CymaBay reports additional Phase II data for seladelpar

CymaBay Therapeutics Inc. (NASDAQ:CBAY) reported additional interim data from a Phase II trial of seladelpar (MBX-8025) to treat primary biliary cholangitis (PBC) in patients who had an inadequate response or intolerance to ursodeoxycholic acid. The...